Dopamine induces a biphasic modulation of hypothalamic ANF neurons: a ligand concentration-dependent effect involving D5 and D2 receptor interaction

Molecular Psychiatry

Volumn 5, Issue 1, 2000, Pages 39-48

  Lee, D ^a   Huang, W ^a   Lim, A T ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Adenylyl cyclases; Atrial natriuretic factor producing neurons; CHO cells; Dopamine receptor subtypes; G proteins; Primary neuron cultures; Receptor gene co expression; Triple staining

Indexed keywords

ADENYLATE CYCLASE; ATRIAL NATRIURETIC FACTOR; CYCLIC AMP; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 5 RECEPTOR; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; NEUROLEPTIC AGENT; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ARTICLE; BIOCHEMISTRY; CELL FUNCTION; CHO CELL; CONTROLLED STUDY; HOST CELL; HYPOTHALAMUS; LIGAND BINDING; MOLECULAR INTERACTION; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033952831     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000601     Document Type: Article

References (46)

1. 1 Civelli O, Bunzow JR. Grandy DK, Zhou QY, Van Tol HHM. Molecular biology of the dopamine receptors. Eur J Pharmacol 1991; 207: 227-286.
2. 2 Hartman DS, Civelli O. Molecular attributes of dopamine receptors: new potential for antipsychotic drug development. Ann Med 1996; 28: 211-219.
3. 3 Sanyal S, Van Tol HH. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. J Psychiatr Res 1997; 31: 219-232.
4. 4 Weinberger DR. The biological basis of schizophrenia: new directions. J Clin Psychiatry 1997; 58Suppl 10:22-27.
5. 5 Wolfarth S, Ossowska K. Dopamine receptors - the present state of research and perspectives. Pol J Pharmacol 1995; 47: 207-218.
6. 6 Brunello N, Masotto C, Steardo L, Markstein R, Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 1995; 13: 177-213.
7. 7 Seeman P, Van Tol HH. Dopamine receptor pharmacology. Trends Pharmncol Sci 1994; 15: 264-270.
8. 8 Hartman DS, Lanau F. Diversity of dopamine receptors: new molecular and pharmacological developments. Pol J Pharmacol 1997; 49: 191-199.
9. 9 Lachowicz JE, Sibley DR. Molecular characteristics of mammalian dopamine receptors. Pharmacol Toxicol 1997; 81: 105-113.
10. 10 Ogawa N. Molecular and chemical neuropharmacology of dopamine receptor subtypes. Acta Med Okayama 1995; 49: 1-11.
11. 11 Rappaport MS, Sealfon SC, Prikhozhan A, Huntley GW, Morrison JH. Heterogeneous distribution of D1, D2 and D5 receptor mRNAs in monkey striatum. Brain Res 1993; 616: 242-250.
12. 12 De Keyser J. Subtypes and localization of dopamine receptors in human brain. Neurochem Int 1993; 22: 83-93.
13. 13 Huntley GW, Morrison JH, Prikhozhan A, Sealfon SC. Localization of multiple dopamine receptor subtype mRNAs in human and monkey motor cortex and striatum. Brain Rex Mol Brain Res 1992; 15: 181-188.
14. 14 Tiberi M, Jarvie KR, Silvia C, Falardeau P, Gingrich JA, Godinot N at al. Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. Proc Natl Acad Sci USA 1991; 88: 7491-7495.
15. 15 Meador Woodruff JH, Mansour A, Grandy DK, Damask SP, Civelli O, Watson SJJ. Distribution of D5 dopamine receptor mRNA in rat brain. Neurosci Lett 1992; 145: 209-212.
16. 16 Bergson C, Mrzljak L, Smiley JF, Pappy M, Levenson R, Goldman Rakic PS. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J Neurosci 1995; 15: 7821-7836.
17. 17 Meador Woodruff JH, Grandy DK, Van Tol HH, Damask SP, Little KY, Civelli O et al. Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology 1994; 10: 239-248.
18. 18 Piomelli D, Pilon C, Giros B, Sokoloff P, Martres MP, Schwartz JC. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature 1991; 353: 164-167.
19. 19 Lee D, Huang W, Copolov DL, Lim AT. D2 receptors mediate dopamino suppression of irANF release and pro-ANF mRNA expression of rat hypothalamic neurons in culture. Mol Cell Neurosci 1994; 5: 523-529.
20. 20 Lee D, Huang W, Lim AT. D1 receptors mediate dopamine stimulation of irANF release and pro-ANF mRNA expression of rat hypothalamic neurons in culture. Endocrinology 1995; 131: 911-918.
21. 21 Lee D, Dong P, Copolov DL, Lim AT. D5 dopamine receptors mediate estrogen-induced stimulation of hypothalamic ANF neurons. Mol Endocrinol 1999; 13: 344-352.
22. 22 Huang VV, Choi CL, Yang Z, Copolov DL, Lim AT. Forskolin induced immunoreactive atrial natriuretic peptide secretion and pro-ANP mRNA expression of hypothalamic: neurons in culture: modulation by glucocorticoids. Endocrinology 1991; 128: 2591-2600.
23. 23 Lee D, Huang W, Yang Z, Copolov DL, Lim AT. In vitro evidence for modulation of morphological and functional development of hypothalamic ir-ANP neurons by 3'5'-cyclic-adenosine monophosphate. Endocrinology 1992; 131; 911-918.
24. 24 Lee D, Huang W, Copolov DL, Lim AT. Glucocorticoids inhibit D1b, but not D2, receptor-mediated effects on hypothalamic atrial natriuretic factor neurons. Endocrinology 1995; 136: 5570-5576.
25. 25 Huang W, Lee D, Yang Z, Copolov DL, Lim AT. Norepinephrine stimulates immunoreactive (ir) alrial natriuretic peptide (ANP) secretion and pro-ANP mRNA expression from rat hypothalamic neurons in culture: effect of α2-adrenoceptors. Endocrinology 1992; 130: 2426-2428.
26. 26 Alonso G, Szafarczyk A, Assenmacher I. Immunoreactivity of hypothalamo-neurohypophysial neurons which secrete corticotrophinreleasing hormone (CRH) and vasopressin (Vp): immunocytochemical evidence for a correlation with their functional state in colchicine treated rats. Exp Brain Res 1986; 61: 497-505.
27. 27 Bush AI, Huang W, Copolov DL, Lim AT. Hypothalamic atrial natriuretic peptide secretion plasticity: differential modulation of α-and β-adrenoceptors. Neuroendocrinology 1990; 52: 65-69.
28. 28 Lim AT, Dean B, Copolov DL. Evidence for post-translational processing of auriculin B to atriopeptin III immediately prior to secretion by hypothalamic neurons in culture. Endocrinology 1990; 127: 2598-2600.
29. 29 Huang W, Lee D, Yang Z, Copolov DL, Lim AT. Plasticity of adrenoceptor responsiveness on irANP secretion and pro-ANP mRNA expression in hypothalamic neuron cultures: modulation by dexamethasone. Endocrinology 1992; 131: 1562-1564.
30. 30 Marley PD, Thomson KA, Jachno K, Johnston MJ. Histamineinduced increases in cyclic AMP levels in bovine adrenal medullary cells. Br J Pharmacol 1991; 104: 839-846.
31. 31 Huang W. Lee D, Yang Z, Casley DJ, Throsby M, Copolov DL et al. Evidence for ANP (5-28) production by rat placental cytotrophoblasts. Endocrinology 1992; 131: 919-924.
32. 32 Throsby M, Lee D, Huang W, Yang Z, Copolov DL, Lim AT. Evidence for ANP(5×28) production by macrophages of the rat spleen: an immunochemical and non-radioactive in situ hybridization approach. Endocrinology 1991; 129: 991-1000.
33. 33 Throsby M, Yang Z, Lee D, Huang W, Copolov DL, Lim AT. Coexpression of atrial natriuretic factor and β-endorphin in a subpopulation of rat splenic macrophages: age related differences. Endocrinology 1993; 133: 2889-2896.
34. 34 Hayes G, Biden TJ, Selbie LA, Shine J. Structure subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a hoterologous cell line. Mol Endocrinol 1992; 6: 920-926.
35. 35 Civelli O, Bunzow JR, Grandy DK. Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 1993; 33: 281-307.
36. 36 Sibley DR, Monsma FJJ, Shen Y. Molecular neurobiology of dopaminergic receptors. Int Rev Neurobiol 1993; 35: 391-415.
37. 37 Ogawa N. Molecular and chemical neuropharmacology of dopamine receptor subtypes. Acta Med Okayama 1995; 49: 1-11.
38. 38 Nozaki M, Sperelakis N. Cholera toxin and Gs protein modulation of synaptic transmission in guinea pig mesenteric artery. Eur J Pharmacol 1991; 197: 57-62.
39. 39 Mousli M, Bueb JL, Bronner C, Rouot B, Landry Y. G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci 1990; 11: 358-362.
40. 40 Tiberi M, Caron MG. High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. J Biol Chem 1994; 269: 27925-27931.
41. 41 Kimura K, White BH, Sidhu A. Coupling of human D-1 dopamine receptors to different guanine nucleotide binding proteins. Evidence that D-1 dopamine receptors can couple to both Gs and G(o). J Biol Chem 1995; 270: 14672-14678.
42. 42 Tang WJ, Gilman AG. Type-specific regulation of adenylyl cyclase by G protein βτ subunits. Science 1991; 254: 1500-1503.
43. 43 Clapham DE, Neer EJ. Now roles for G-protein beta gamma-dimers in transmembrane signalling. Nature 1993; 365: 403-406.
44. 44 Pieroni JP, Jacobowitz O, Chen JQ, Lyengar R. Signal recognition and integration by Gs-stimulated adenylyl cyclases. Curr Opin Neurobiol 1993; 3: 345-351.
45. 45 Tang WJ, Gilman AG. Adenylyl cyclases. Cell 1992; 70: 869-872.
46. 46 Iyengar R. Molecular and functional diversity of mammalian Gs-stimulated adenylyl cyclases. FASEB J 1993; 7: 768-775.